Larazotide 

Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection^[1][2].

Larazotide (1-100 μM; 5 d) affects Vero cell growth^[1].
Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively^[1].
Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells^[2].
Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers^[2].
Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

725.83

C₃₂H₅₅N₉O₁₀

258818-34-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427.  [Content Brief]

  [2]. Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94.  [Content Brief]